|Goldman Small Cap Research Covers MedClean (OTC:MCLN)|
|By Staff and Wire Reports|
|Wednesday, 09 December 2009 07:52|
Senior research analyst rates MedClean a "Speculative Buy" and believes share price could reach $0.40 early next year as the company executes its plan.
Former Piper Jaffray's Technology analyst Rob Goldman, who brings over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager has initiated coverage on MedClean Technologies Inc. (OTC:MCLN).
During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.